Get the Stockscreener App
17.39
0.11%
-0.02
After Hours:
17.45
0.06
+0.35%
Takeda Pharmaceutical Co Adr stock is traded at $17.39, with a volume of 1.95M.
It is down -0.11% in the last 24 hours and up +5.46% over the past month.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
See More
Previous Close:
$17.41
Open:
$17.47
24h Volume:
1.95M
Relative Volume:
0.57
Market Cap:
$55.54B
Revenue:
$29.91B
Net Income/Loss:
$1.30B
P/E Ratio:
42.87
EPS:
0.4056
Net Cash Flow:
$3.49B
1W Performance:
+2.17%
1M Performance:
+5.46%
6M Performance:
-5.80%
1Y Performance:
+17.74%
1-Day Range:
$17.36
$17.47
1-Week Range:
$17.35
$17.64
52-Week Range:
$12.99
$18.89
Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile
Compare TAK vs HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TAK
Takeda Pharmaceutical Co Adr
|
17.39 | 55.60B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.80 | 43.16B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.52 | 42.81B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
75.84 | 30.39B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
501.27 | 21.95B | 3.17B | 1.29B | 1.01B | 27.09 |
Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-26 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-13-26 | Resumed | Morgan Stanley | Overweight |
| Apr-02-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-16-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-19-22 | Upgrade | Cowen | Market Perform → Outperform |
| Oct-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-19-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-19 | Initiated | Cowen | Market Perform |
| Aug-15-19 | Downgrade | Daiwa Securities | Outperform → Neutral |
View All
Takeda Pharmaceutical Co Adr Stock (TAK) Latest News
Takeda Pharmaceutical Company Limited (TAK) Stock Price, News, Quote & History - Yahoo! Finance Canada
Takeda Pharmaceutical Company Limited (TAK) stock price, news, quote and history - au.finance.yahoo.com
Takeda (TAK) Q1 2026 Earnings Call Transcript - theglobeandmail.com
Murata ADR Surges 15%, SoftBank Group Jumps 7% as Semiconductor, Tech Stocks See Short-Covering - finance.biggo.com
Takeda Pharma ADR earnings beat by $0.06, revenue topped estimates - Investing.com
Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026 - GlobeNewswire Inc.
Teva Pharmaceutical Industries Limited (TEVA) stock price, news, quote and history - Yahoo Finance UK
TAK: Takeda Pharmaceutical Co Ltd (ADR) Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Takeda invests $30M to build Indonesian plasma ecosystem - grafa.com
Form 144 Takeda Pharmaceutical Company Limited For: 13 July By Investing.com - Investing.com Canada
6 High-Yield International Dividend Stocks Analysts Love - Forbes
ETFs Investing in Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stocks - TradingView
TAKTakeda Pharmaceutical Co ADR Latest SEC Filings - Finviz
India Celiac Disease Treatment Market Size & Outlook, 2033 - Grand View Research
0A87 Forecast — Price Target — Prediction for 2027 - TradingView
TAK-755 from Takeda Pharmaceutical Co.enzyme replacement for a rare bleeding disorder - Ad-hoc-news.de
TKDA Forecast — Price Target — Prediction for 2027 - TradingView
Takeda Pharmaceutical Co. Ltd. Sponsored ADR Actuals & Estimates (LS:A1CWZF) - TradingView
A1CWZF Forecast — Price Target — Prediction for 2027 - TradingView
TAK/N Forecast — Price Target — Prediction for 2027 - TradingView
Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR - TradingView
Takeda Pharmaceutical Co. Ltd. Sponsored ADR Actuals & Estimates (GETTEX:TKDA) - TradingView
Takeda Pharmaceutical StockAnalyst sentiment and chart picture on Thursday - AD HOC NEWS
Why Takeda’s Entyvio subcutaneous dose is changing quiet routines for gut patients - AD HOC NEWS
Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data - Sahm
Takeda Pharmaceutical Co Ltd (TAK) Stock Price, Trades & News - GuruFocus
Takeda zasocitinib beats deucravacitinib in Phase 3 psoriasis trial - grafa.com
Astellas Pharma Inc. (ALPMY) Stock Price, News, Quote & History - Yahoo Finance
Takeda Pharmaceutical (TAK) Posts Modest Gain: Support Holds, Resistance NearsDescending Triangle - newsline.com
Takeda (TAK) Edges Higher: Approaching Key Resistance Amid Steady Pharma DemandDemand Zone - newsline.com
Dell Upgraded, Costco Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Takeda Pharmaceutical (ADR) stock (US8740602052): shares fall in New York after shelf registration u - AD HOC NEWS
Takeda Pharmaceutical Co Adr Stock (TAK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
0.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):